Month: January 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection -- Company expects...

error: Content is protected !!